Virus-based immunotherapies to transform the fight against cancers and infectious diseases. September 2018 First Half 2018 & Business Update
|
|
- Derek Caldwell
- 5 years ago
- Views:
Transcription
1 Virus-based immunotherapies to transform the fight against cancers and infectious diseases September 2018 First Half 2018 & Business Update
2 Disclaimer This presentation contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently under way, (ii) regulatory authorities will agree with the Company s further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company s activities, perspectives, financial situation, results and development. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ( Facteurs de Risques ) section of the Document de Référence, available on the AMF website ( or on Transgene s website ( Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forwardlooking statements, even if new information becomes available in the future. 2
3 Management Experienced team focused on delivery Philippe Archinard, PhD Chairman & Chief Executive Officer Eric Quéméneur, PhD Executive VP and Chief Scientific Officer E C Christophe Ancel, PharmD VP Quality and Qualified Person Maud Brandely, MD, PhD Chief Medical Officer A B C D E F A B D Jean-Philippe Del VP Finance Thibaut du Fayet, MBA VP Marketing, Alliance, and Project Mgt John Felitti, JD, MBA General Counsel and VP Legal F Hemanshu Shah, PhD, MBA VP Corporate Development & Medical Affairs 3
4 Transgene Poised to play a key role in immunotherapy A pioneer in developing virus-based immunotherapies Focus on cancers High level of unmet medical need New treatments create significant opportunities 2 Cutting-edge technologies Therapeutic vaccines Oncolytic viruses 5 Immunotherapy products in clinical trials focus on combination regimens 4
5 Dense activity since January 2018 $48 million Sale of TG1050 and TG6002 rights in Greater China to Tasly Biopharmaceuticals (July 2018) $48 million in Tasly Biopharmaceuticals shares Key clinical trials Progress on key clinical trials to deliver results by the end of 2018 and in 2019 ASCO Invir.IO TM New positive data on Pexa-Vec IV Translational data showed strong anti-tumor activity and one pathological response (n=4) Progress of our novel oncolytic virus platform First candidate to enter the clinic in
6 Cutting-edge molecular virology applied to Immuno-Oncology Therapeutic vaccines Oncolytic Viruses Broad and sustained anti-tumor response Targeted response against selected TAAs Increase CD4+ and CD8+ T cells Synergies with other therapies Well tolerated Sustained anti-tumor response via immunogenic cell death Increase infiltration of T and NK cells Potential to express anti-cancer weapons to modulate the Tumor Micro Environment (TME) Synergies with other therapies Well tolerated 6
7 A broad pipeline of clinical-stage immunotherapeutics Transgene strategic trials Product THERAPEUTIC VACCINES Indication Preclinical Clinical Phase Phase 1 Phase 2 Phase 3 TG4010 Non-small cell lung cancer 1 st line + nivolumab (ICI) + CT * TG4001 Recurrent HPV-positive head and neck cancers + avelumab (ICI) * TG1050 Chronic hepatitis B + antiviral ** ONCOLYTIC VIRUSES Pexa-Vec Advanced HCC 1 st line (PHOCUS) + sorafenib *** Advanced HCC 1 st line + nivolumab (ICI) TG6002 Colorectal cancer ** * Clinical collaboration / ** Rights acquired for Greater China ***Transgene has commercial rights to Pexa-Vec in Europe and additional selected countries. 7
8 Invir.IO TM platform Oncolytic viruses with multiple MoAs Leverage our proprietary large capacity Vaccinia virus Enhanced modulation of the tumor micro-environment (TME) Designing the next generation of multifunctional oncolytic viruses ❶ Tumor cell lysis induced after specific viral replication in tumor cells ❷ Immunogenic cell death and recruitment of T cells ❸ Local release of active payload (transgenes) in the TME Preclinical candidates in development 2 research collaborations signed First candidate in clinic in 2019 IT and IV administrations 8
9 Therapeutic Vaccines Pioneering virus-based immunotherapeutics 9
10 TG4010 in non-small cell lung cancer (NSCLC) MVA coding for MUC1 and IL2
11 Lung cancer Better therapeutic options still needed for non-responders (ICIs) Dismal prognosis at late stage Need to increase response rate and OS Min. 350 K patients 1L* Min. 270 K patients 2L* First-line therapy Pembrolizumab registered in 2016 for patients whose tumor cells express high levels of PD-L1 ( 50 %) in 2017 (USA) and 2018 (EU) for all patients, in combination with pemetrexed/ carboplatin CT Second-line therapy Several anti PD-1/PD-L1 registered since 2015 (Nivolumab) Still a major unmet need as a majority of patients do not respond to ICIs *Source: USA, EU, JP, Globocan, Company estimates 11
12 TG4010 Compelling lung cancer clinical data Improved response rate & duration of response SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS) TG4010 in combination with chemotherapy for 1 st line NSCLC TG chemotherapy 40.9 [ ] wks Non-squamous (n) ORR Median duration of response (wks) TG CT 98 40% 41 Placebo + CT 98 28% 18 Chemotherapy (n=27) 18.1 [ ] wks Placebo + chemotherapy 18.1 [ ] wks Improved response rate & duration of response Good safety profile Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 12
13 TG4010 Compelling lung cancer clinical data Well positioned for further development in NSCLC SUCCESSFUL PHASE 2B TRIAL (RANDOMIZED, PLACEBO-CONTROLLED, 222 PATIENTS) TG4010 in combination with chemotherapy for 1 st line NSCLC Progression-free survival (months) Patients with non sq. tumors (n=196) Overall survival (months) Patients with non sq. tumors (n=196) Significant improvements in PFS and OS in patients in patients with non sq. tumors TG chemotherapy Placebo + chemotherapy 35% 19% TG chemotherapy Placebo + chemotherapy 36% 20% Clinical efficacy in both PD-L1 negative and PD-L1 positive patients Source: Quoix, E. et al., TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, The Lancet Oncology, Dec. 2015, (17:212) 13
14 TG4010 1L To increase ORR with triple combination regimen in patients expressing low levels of PD-L1 (<50%) Recruitment continues and additional centers are being activated Proof-of-concept Phase 2 trial Collaborative agreement with BMS (supply of nivolumab) First patient treated in January 2018 Recruitment to be completed in 2Q 2019 Primary endpoint evaluation expected in 2H 2019 (ORR on 35 patients) Endpoints Primary endpoint: Objective response rate (ORR) Secondary endpoints: duration of response, disease control rate, progression-free survival (PFS), overall survival (OS), and safety Protocol Up to 39 patients (35 evaluable patients) Multi-center, single-arm, open label study Stage IIIB-IV or delayed relapse, tumors with low or undetectable PD-L1 expression (<50%) Study regimen TG PFU weekly for 6 weeks then every 3 weeks by SC route Nivolumab 360 mg every 3 weeks by IV route Pemetrexed-carboplatin (or cisplatin) every 3 weeks for 4 cycles followed by pemetrexed maintenance Participating countries USA Belgium Denmark France Hungary 14
15 TG4001 & TG1050 Ongoing trials to deliver results in 2018 TG4001 HPV+ head & neck cancers MVA encoding for HPV16 E6 & E7 Clinical collaboration with Merck/Pfizer, supply of avelumab (ICI) Phase 1b/2 trial PI: Prof. Christophe Le Tourneau (Institut Curie, Paris) First patient treated in September 2017 Following positive safety evaluation, Phase 2 part ongoing and additional sites being activated Phase 1 results in 4Q 2018 (n=9 patients) Next clinical readout expected in 2H 2019 TG1050 Chronic hepatitis B Adeno encoding for 3 HBV antigens Phase 1 trial completed Primary endpoint met: good safety profile confirmed - single and multiple doses (AASLD 2017) Full results to be presented in 4Q 2018 at a major liver conference Rights for Greater China acquired by Tasly Pharmaceuticals (July 2018) 15
16 Oncolytic Viruses Pioneered by Transgene A new and highly promising therapeutic class in the fight against cancer. Transgene leading the development of multifunctional OVs for the enhanced modulation of the TME via a single therapeutic.
17 Oncolytic viruses Rising interest from Pharmas in exciting approach 1 st OV approved (Imlygic) M&As and collaborations signed (e.g. Viralytics, Benevir, PsiOxus ) Validates market potential of oncolytic approaches Jan st patient treated in Pexa-Vec Phase 3 Sep 2017 Launch OV platform for a new OV generation Oct st patient treated in TG6002 s Phase 1 Jun 2018 New data on Pexa-Vec presented at ASCO Jul 2018 Tasly Bio. acquires rights for TG6002 in China Mid 2019 Interim analysis on Pexa-Vec + nivo in HCC (ORR) 1 st product in clinic 17
18 Pexa-Vec Targeting solid tumors Replicative Vaccinia Virus expressing GM-CSF
19 Pexa-Vec Lead oncolytic virus Transgene owns development and commercialization rights in Europe Licensor: SillaJen (KOSDAQ: ) HCC 1L Global Phase 3 trial Combination Phase 2 trial conducted by Transgene Global clinical development plan Other solid tumors Exploratory Phase 2 trials conducted by Transgene Exploratory Phase 1 trials led by SillaJen (RCC 2L, CRC 2L/3L) 19
20 Pexa-Vec Large unmet medical need in HCC Dismal prognosis Better therapeutic options needed 25,000 eligible patients in Europe* First-line therapy Sorafenib - modest activity ORR: 2% ; median OS: 10.7 months Lenvatinib recently approved with non-inferiority results (USA, EU, Japan) Nivolumab could become a new therapeutic option: Promising activity in Phase 3 (still ongoing) Second-line therapy Regorafenib ORR: 10%; median OS: 10.6 months Nivolumab approved by FDA ORR: 18%; median OS: 15.6 months * Source: Globocan, Company estimates 20
21 Pexa-Vec Key Phase 2 clinical trial results Clinical activity demonstrated in multiple trials Trials with >300 patients treated with Pexa-Vec in variety of tumor types, including liver, colorectal and kidney Proof of concept for MOA: active immunotherapy 30-patient dose-finding Phase 2 trial in HCC (80% of patients first-line) OS results - high dose versus low dose Median OS: 14.1 (high dose) vs. 6.7 months (low dose) Hazard Ratio = 0.39 p = Nature Medicine, Volume 19, Issue 2, February
22 Pexa-Vec Triggers antitumor immunity after single IV administration Prior to planned surgery of locally advanced, poor prognosis or metastatic cancers Pexa-Vec shown to Selectively target tumor tissue after single IV administration Stimulate the adaptive and innate anti-tumor immune response Induce expression of PD-L1 and PD-1 pathways One complete and one partial tumor pathological response at the time of surgery on four evaluable CRLM patients Presence of Pexa-Vec in tumor tissue Single i.v. Pexa-Vec Surgery PBMCs exhibited robust activation by 24 hrs post-infusion Expression of CD69 (an early activation marker) was enhanced on effector cell populations, notably NK & T cells Expression of PD-L1 was increased CD69 Post-surgery d1 d2 d3 d5 d14 ± 4d 1m 3m Peripheral blood samples collected n = 8 ; 3 with metastatic melanoma and 5 with colorectal cancer metastases to the liver (CRLM) PD-L1 Normal tissue CRLM tissue showing expression of Pexa-Vec, signs of inflammation and fibrosis, necrotic cells Data support ongoing development of Transgene s Vaccinia virus-based oncolytics Source: Samson, A. et al, Single intravenous preoperative administration of the oncolytic vaccinia virus Pexa-Vec to prime anti-tumor immunity, ASCO 2018, June
23 Pexa-Vec Clinical development plan in HCC - 1 st line Pivotal Phase 3 and combination Phase 2 Position Pexa-Vec with current and future standard of care Advanced HCC 1 st line Phase 3 Pexa-Vec + sorafenib Conducted by Advanced HCC 1 st line Phase 1/2 Pexa-Vec + Opdivo (nivolumab) Sponsor Multi-center Phase 3 trial in Europe, USA, Asia Randomized, two-arm trial Ongoing global recruitment First patient included in China in Sept First data (efficacy vs SoC) expected in 2019 Multi-center Phase 1/2 trial in France, Italy, USA Open-label, single-arm trial Safety review committee expected before year-end 2018 Interim analysis (15 patients) expected mid-2019 (primary endpoint ORR) 23
24 TG6002 Advanced OV already in the clinic Viral oncolysis + local production of chemotherapy administered IV Multiple MoAs: ❶ Excellent oncolytic properties ❷ Targeted chemotherapy with FCU1 gene allowing the production 5-FU in the tumor FCU1 gene Unique and proprietary High 5-FC to 5-FU conversion ratio No FCU1 related safety issue Preclinical results confirm potency Gastro-intestinal adenocarcinoma (colon cancer) Multi-center Phase 1/2a trial Regimen: TG6002: D1, D8, D mg/kg/day oral 5-FC prior to TG6002, additional cycles until disease progression Phase 1 part (dose escalation): up to 24 patients Phase 2a part (efficacy): 35 patients IND granted in Belgium, Spain, France First patient expected in coming weeks Glioblastoma Single-center Phase 1 trial Sponsor: AP-HP First patient treated in Oct Greater China rights acquired by Tasly Biopharmaceuticals (July 2018) 24
25 Engineering multifunctional oncolytic viruses Based on large capacity Vaccinia Virus
26 Invir.IO Engineer multifunctional oncolytic viruses To modulate the tumor micro-environment Proprietary virus Anti-cancer Weapons Enhanced modulation of TME + ICIs (Mabs/SdAbs) Enzymes Ligands Chemokines Restore T-cell/tumor interaction Depletion of Tregs Depletion of immuno-suppressive metabolites Activate immunological pathway Favor infiltration of CD8-T cells and/or DCs (Anti-CTLA-4 Abs)* (SdAbs) Oncolytic activity Immunogenic properties Tumor targeting from the IV route Cytokines Proliferation of NK, B, and T cells (not Tregs) Induction of memory CD8+-T cells Future pipeline of novel OV drugs * Vargas F. et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell, April 2018, (33, 1-15) 26
27 OV encoding for anti-ctla-4 mab Improving on validated MoA of ipilimumab Preclinical PoC Building a potent multifunctional OV Transgene s OVs deliver functional mab in the TME (1) BioInvent s full length human recombinant anti-ctla-4 Abs promote depletion of intratumoral Treg cells (2) Improved efficacy compared to combination of separate Ab and OV (1) Longer duration of expression Expected improved tolerability owing to lower systemic antibody exposure in peripheral nontumor compartments Indications: multiple solid cancers (1) Kleinpeter P. et al., Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scfv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition, OncoImmunology, Oct (5:10) (2) Vargas F. et al., Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies, Cancer Cell, April 2018 (33: 1-15) 27
28 Outlook On track to deliver multiple value-enhancing clinical data readouts and preclinical milestones
29 Company funded to deliver multiple value generating milestones Key figures 33.0 million 3.5 million Cash and cash equivalents as of June 30, 2018 Operating revenues as of June 30, 2018 Key shareholders As of the end of mid September, % 8.4 million Cash burn for the first half 2018 Free float 43 % 25 million Expected cash burn for 2018 Financial visibility until the end of September 2019 Market capitalization: ~ 200 million as of September 18, million shares outstanding million options and restricted stocks Listed on Euronext Paris ISIN: FR Ticker: TNG 29
30 Significant anticipated value-creating news flow Portfolio to deliver news flow in the near-term 4Q H H 2019 TG6002 GI 1 st patient treated TG1050 Phase 1/1b results Pexa-Vec + nivo 1L HCC Safety review committee TG4001 SCCHN Phase 1 results on 9 patients TG4010 1L NSCLC Recruitment completed TG4010 1L NSCLC ORR on 35 patients Pexa-Vec + nivo 1L HCC Interim analysis (ORR) on 15 patients TG4001 SCCHN Next clinical readout Transgene to enter personalized medicine field Pexa-Vec Phase 3 1L HCC First readout Invir.IO 1 st product in clinic Clinical resuts Study milestone Preclinical activity 30
31 We would like to thank patients, clinicians and support personnel for their commitment to the fight against severe diseases 31
32 Contact Lucie Larguier Director Corporate Communication and Investor Relations / larguier@transgene.fr / Transgene 400 Boulevard Gonthier d Andernach - Parc d Innovation - CS Illkirch Graffenstaden Cedex France Tél.: + 33 (0)
Virus-based immunotherapies to transform the fight against cancers and infectious diseases. March 21, 2018 FY Results 2017 & Business update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases March 21, 2018 FY Results 2017 & Business update Disclaimer This presentation contains forward-looking statements,
More informationViral-vector based immunotherapies to transform the fight against cancer and infectious diseases. January, 2019
Viral-vector based immunotherapies to transform the fight against cancer and infectious diseases January, 2019 Disclaimer This presentation contains forward-looking statements, which are subject to numerous
More informationVirus-based immunotherapies to transform the fight against solid tumors and infectious diseases. March 2019 Full Year Results 2018 & Business Update
Virus-based immunotherapies to transform the fight against solid tumors and infectious diseases March 2019 Full Year Results 2018 & Business Update Disclaimer This presentation contains forward-looking
More informationViral-based immunotherapies to transform the fight against cancers and infectious diseases. November 2017 Corporate Presentation
Viral-based immunotherapies to transform the fight against cancers and infectious diseases November 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, which are
More informationJefferies Healthcare Conference, London, November 19-20, Elisabetta Castelli PhD Director Investor Relations
Jefferies Healthcare Conference, London, November 19-20, 2014 Elisabetta Castelli PhD Director Investor Relations SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the
More informationFirst half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed Seven active clinical trials: o First patients treated in four combination trials
More informationTransgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials Programs progressing in line with strategy Significant reduction of net loss: 12.2 million compared to
More informationTransgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy
Transgene Reviews Product Pipeline, Provides a Business Update and Outlines its Corporate Strategy Parc d Innovation, Illkirch, France, March 22, 2010 Transgene (Euronext Paris: FR0005175080) details its
More informationTransgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
2017 Full-year results and business update Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses All clinical programs made progress o o 7 clinical
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationMOLOGEN AG Jefferies 2014 London Healthcare Conference
Jefferies 2014 London Healthcare Conference Dr. Matthias Schroff Chief Executive Officer London 20 November 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationMOLOGEN AG. Pioneering Immune Therapy. Annual Results Analysts Call March 25, 2014
Pioneering Immune Therapy Annual Results 2013 Analysts Call March 25, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More information9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO
9M RESULTS 2014 CONFERENCE CALL DR. MATTHIAS SCHROFF, CEO BERLIN, 13 NOVEMBER, 2014 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future or future developments,
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationTHE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016
THE FUTURE OF VACCINES ASCO ANNUAL MEETING JUNE 4, 2016 1 BAVARIAN NORDIC INVESTOR & ANALYST UPDATE & RECEPTION Welcome and Introduction to Bavarian Nordic s Cancer immunotherapy Programs Paul Chaplin,
More informationONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan
ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,
More informationTG4010. Public Information
TG4010 Public Information 11 May 2017 Public Information 11 May 2017 Page 2 /7 ABBREVIATIONS DNA Deoxyribonucleic acid GMO Genetically modified organism IL2 Interleukin-2 IM Intramuscular IT Intratumoral
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationIMMUNOTHERAPY IMMUNOTHERAPY. 37th Annual JPMorgan Healthcare Conference
NEXT-GENERATION NEXT GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY 37th Annual JPMorgan Healthcare Conference 2 Safe harbor Any statements contained herein that are not statements of historical
More informationINTERIM RESULTS AS OF JUNE 30, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2014 Q2 AUGUST 28, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 2.6 million doses IMVAMUNE delivered to the SNS during H1 (0.9 million in Q2) Increased contribution
More informationINTERIM RESULTS AS OF JUNE 30, 2017
INTERIM RESULTS AS OF JUNE 30, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationINTERIM RESULTS AS OF MARCH 31, 2018
INTERIM RESULTS AS OF MARCH 31, 2018 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationQ Financial Update November 6, 2018 NASDAQ:FPRX
Q3 2018 Financial Update November 6, 2018 NASDAQ:FPRX 2 Forward-Looking Statements Disclaimer Forward-looking statements contained in this presentation include statements regarding (i) the timing of initiation,
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationINTERIM RESULTS AS OF JUNE 30, 2016 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF JUNE 30, 2016 Q2 CSE/OMX:BAVA, OTC:BVNRY FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationImmuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationNASDAQ & TSX: IMV. BIO Investor Forum. October IMV Inc. All rights reserved.
NASDAQ & TSX: IMV BIO Investor Forum October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationJefferies 2017 Global Healthcare Conference. Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer
Jefferies 2017 Global Healthcare Conference Stephen Doberstein, Ph.D. Senior Vice President & Chief Scientific Officer June 7, 2017 This presentation includes forward-looking statements regarding Nektar
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour
More informationMedia Release. Basel, 26 March 2018
Media Release Basel, 26 March 2018 Phase III IMpower150 study showed Roche s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationDISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL
DISCOVERING AND DEVELOPING NEW IMMUNE ACTIVATING MECHANISMS AND ANTIBODIES TO IMPROVE CANCER SURVIVAL Annual General Meeting 24 April 2018 Björn Frendéus, Acting CEO & CSO 1 IMMUNOTHERAPY HAS TRANSFORMED
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for General Oncology Presentation Outline 1. Immunomic Therapeutics: corporate overview 2. Unmet need in cancer immunotherapy
More informationDetermined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017
Determined to realize a future in which people with cancer live longer and better than ever before CORPORATE PRESENTATION JUNE 2017 1 Forward-looking statements disclosure This presentation contains forward-looking
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationINTERIM RESULTS AS OF MARCH 31, 2014 CSE/OMX:BAVA, OTC:BVNRY
INTERIM RESULTS AS OF MARCH 31, 2014 Q1 MAY 14, 2014 CSE/OMX:BAVA, OTC:BVNRY FINANCIAL HIGHLIGHTS 1.7 million doses delivered to the SNS during Q1 Full year financial expectations maintained DKK million
More informationJP Morgan Healthcare Conference
JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and
More informationMedia Release. Basel, 07 December 2017
Media Release Basel, 07 December 2017 Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent
More informationMOLOGEN AG. Company Presentation October 2015
Company Presentation October 2015 Agenda Business Overview Market MGN1703 Cancer Immunotherapy MGN1601 Therapeutic Vaccination against Cancer EnanDIM New Generation of Immunomodulators Key Financials and
More informationIMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018
NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationImmunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma
PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading
More informationCorporate Overview. June 2018 NASDAQ:FPRX
Corporate Overview June 2018 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationCorporate Presentation
Corporate Presentation October 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine s current expectations
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) June 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More information